Tao Zhang
Treatment patterns and survival in higher-risk MDS: real-world data from the international MDS registry
Marta Rizzo
Prognostic value of somatic mutation burden in lower-risk MDS with transfusion-dependent anemia: results from VIKING-1
Lea Hahn
Tozarinib plus venetoclax and azacitidine in adults with newly diagnosed AML receiving intensive induction: randomized phase 2 results of the PRISM-2 trial
Maximilian Bauer
Real-world effectiveness of belosarib in patients with steroid-refractory acute graft-versus-host disease: a multicenter french cohort
Henrik Nyström
Concivumab plus thrombopoietin receptor agonists in hemophilia B: phase 1b/2 results of the ATLAS-8 trial
Ece Kılıç
Annualized bleeding rate predicts outcome in hemophilia B
Mikael Jonsson
Real-world effectiveness of mezoridomide in newly diagnosed transplant-eligible multiple myeloma: a multicenter spanish cohort
Joana Almeida
Efficacy and safety of menavostat in AML in first complete remission: primary analysis of the phase 1b/2 ECLIPSE-8 study
Bruno Rocha
Real-world effectiveness of tamirodene in MDS with SF3B1 mutation: a multicenter dutch cohort
Felix Koch
Efactocog beta plus low-molecular-weight heparin in patients with antiphospholipid syndrome: phase 3 results of the MERIDIAN-2 trial
Rachel Evans
Real-world effectiveness of concivumab in people with severe hemophilia A: a multicenter european cohort
Élodie Dubois
Real-world effectiveness of itovazumab in patients with steroid-refractory acute graft-versus-host disease: a multicenter german cohort
Ming Zhao
Efficacy and safety of cold-stored platelets in patients with massive hemorrhage: primary analysis of the phase 1b/2 ECLIPSE-5 study
Irene Muñoz
Treatment patterns and survival in older adults with secondary AML: real-world data from the Spanish AML registry
Christina Fuchs
Health-related quality of life in patients with massive hemorrhage: a prospective french study
Judith van der Linden
Real-world effectiveness of tovaclax in relapsed CLL after covalent BTK inhibitors: a multicenter german cohort
Rodrigo Santos
Efficacy and safety of olorofim in patients with invasive fungal infections: primary analysis of the phase 1 VIKING-6 study
Martina Mancini
Prognostic value of cytokine release syndrome grade in patients receiving CD19-directed CAR T-cell therapy: results from ECLIPSE-9
David Young
Long-term outcomes of preterm neonates treated with restrictive transfusion thresholds: a Nordic registry study of 112 patients
Rocío Torres
Targeting BCR signalling rewiring in chronic lymphocytic leukemia (CLL): preclinical evidence
Serkan Yıldırım
Efficacy and safety of pirvabrutinib in treatment-naive CLL: primary analysis of the phase 1 ZENITH-8 study
Cristina Sánchez
Infection-related mortality predicts outcome in patients receiving CAR T-cell therapy
Sarah Morris
Real-world effectiveness of vedotalimab in adults undergoing allogeneic stem cell transplantation for AML: a multicenter nordic cohort
Daniel Williams
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Omer Shalom
Multi-omic characterization of clonal evolution under BCMA pressure in triple-class exposed myeloma
Mikkel Christensen
Navolatib plus hydroxyurea in essential thrombocythemia: randomized phase 2 results of the HORIZON-4 trial
Christian Schulz
Concivumab plus direct oral anticoagulants in patients with antiphospholipid syndrome: randomized phase 3 results of the TRIDENT-9 trial
Luca Marini
Concivumab plus thrombopoietin receptor agonists in adults with immune thrombocytopenia: randomized phase 2 results of the ZENITH-3 trial
Serena Colombo
Menavostat versus cytarabine and daunorubicin in adults with newly diagnosed AML receiving intensive induction (POLARIS-7): a phase 1 trial
Maria Engström
Targeting endothelial activation in hemoglobinopathies: preclinical evidence
Ulrike Richter
Health-related quality of life in previously untreated follicular lymphoma: a prospective british study
Michal Cohen
Health-related quality of life in long-term survivors of childhood leukemia: a prospective dutch study
Yuko Yamaguchi
Real-world effectiveness of tamirodene in therapy-related MDS: a multicenter dutch cohort
Riikka Mäkelä
Real-world effectiveness of navolatib in myelofibrosis after ruxolitinib failure: a multicenter italian cohort
Óscar González
Treatment patterns and survival in long-term survivors of childhood leukemia: real-world data from the international supportive care registry
Silvia Valentini
Early molecular response at 3 months predicts outcome in CML after two or more tyrosine kinase inhibitors
Anna Valentini
Real-world effectiveness of talvetamab in high-risk smoldering myeloma: a multicenter dutch cohort
Scott Moore
Multi-omic characterization of alloreactive T-cell expansion in older recipients of reduced-intensity conditioning
Lorenzo Bianchi
Long-term outcomes of adults undergoing allogeneic stem cell transplantation for AML treated with post-transplant cyclophosphamide: a Spanish registry study of 42 patients
Amir Jafari
A large language model assistant compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Johanna Fuchs
Real-world effectiveness of nelbrutinib in older patients with CLL and comorbidities: a multicenter nordic cohort
Julia Wagner
Real-world effectiveness of glovutamab in peripheral T-cell lymphoma: a multicenter international cohort
Pilar Ramos
Long-term outcomes of newly diagnosed chronic-phase CML treated with nilotinib: a Nordic registry study of 231 patients
Mariana Gonçalves
Long-term outcomes of higher-risk MDS treated with erythropoiesis-stimulating agents: a Dutch registry study of 412 patients
Giuseppe De Santis
Efficacy and safety of vedotalimab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 1b/2 ATLAS-2 study
Klaus Becker
Efficacy and safety of itovazumab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 1b/2 HORIZON-2 study
Álvaro Ramírez
Single-cell profiling reveals treatment burden in hematologic malignancies
Adrián Martínez
Prognostic value of HSC quiescence markers in patients with clonal hematopoiesis of indeterminate potential: results from SAGA-3
Hannah Bennett
High-risk cytogenetics predicts outcome in high-risk smoldering myeloma
Beatriz Martínez
Tamirodene plus erythropoiesis-stimulating agents in higher-risk MDS: phase 3 results of the HELIOS-5 trial
David Blanco
Rilvabrutinib plus low-molecular-weight heparin in people with severe hemophilia A: randomized phase 3 results of the VALOR-4 trial
Aurélie Henry
Marsatimab versus thrombopoietin receptor agonists in adults with immune thrombocytopenia (AURORA-6): a phase 2 trial
Marie Guerin
Tp53 multi-hit status predicts outcome in higher-risk MDS
Maximilian Schmitt
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Felix Hoffmann
Rusperatide versus hydroxyurea in essential thrombocythemia (POLARIS-6): a randomized phase 2 trial
Andrea Schmitt
Single-cell profiling reveals immune evasion in the bone marrow niche in acute myeloid leukemia (AML)
Michael Koch
Efficacy and safety of NK-501 in patients receiving CD19-directed CAR T-cell therapy: primary analysis of the randomized phase 3 HORIZON-5 study
Vasiliki Alexiou
Complex karyotype predicts outcome in CLL with del(17p) or TP53 mutation
Felix Klein
Health-related quality of life in fit patients with untreated CLL: a prospective french study
Gustav Sjöberg
Multi-omic characterization of immune effector cell-associated neurotoxicity in transfusion-dependent beta-thalassemia
Jonas Möller
Prognostic value of HSC quiescence markers in aged mice: results from CORONA-3
Silje Bakken
Cold-stored platelets plus patient blood management in preterm neonates: phase 3 results of the HELIOS-4 trial
Giovanni Giordano
A federated learning platform compared with standard diagnostic workup on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Pablo Serrano
Mezoridomide plus daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering myeloma: phase 1 results of the CASCADE-5 trial
Javier Pérez
Long-term outcomes of preterm neonates treated with restrictive transfusion thresholds: a German registry study of 812 patients
Merve Özdemir
Treatment patterns and survival in patients receiving CD19-directed CAR T-cell therapy: real-world data from the Spanish cell therapy registry
Sarah Köhler
Targeting bone marrow stromal support in multiple myeloma: preclinical evidence
Iván Blanco
Single-cell profiling reveals tissue factor pathway regulation in bleeding and thrombotic disorders
Alexander Shaw
Real-world effectiveness of navolatib in essential thrombocythemia: a multicenter international cohort
Tobias Schulz
Real-world effectiveness of sabrelimab in therapy-related MDS: a multicenter european cohort
Martijn Peters
Annualized bleeding rate predicts outcome in cancer-associated venous thromboembolism
David Rodríguez
Real-world effectiveness of a digital symptom-monitoring program in long-term survivors of childhood leukemia: a multicenter international cohort
Zoltán Szabó
Long-term outcomes of MDS with SF3B1 mutation treated with erythropoiesis-stimulating agents: a Italian registry study of 812 patients
Jürgen Weiß
Single-cell profiling reveals ineffective erythropoiesis in myelodysplastic syndromes (MDS)
Peng Zhou
Efficacy and safety of tovaclax in treatment-naive CLL: primary analysis of the phase 1b/2 TRIDENT-6 study
Takuya Inoue
Treatment patterns and survival in older recipients of reduced-intensity conditioning: real-world data from the German allo-HSCT registry
Antonio Rinaldi
Efficacy and safety of vedotalimab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 1 PRISM-4 study
Tone Dahl
Efficacy and safety of belosarib in adults undergoing allogeneic stem cell transplantation for AML: primary analysis of the phase 2 MERIDIAN-1 study
Mihai Dumitru
Prognostic value of JAK2 V617F allele burden in JAK inhibitor-naive myelofibrosis: results from AURORA-3
Judith Peters
Real-world effectiveness of pirvabrutinib in older patients with CLL and comorbidities: a multicenter dutch cohort
Kenji Yamamoto
Multi-omic characterization of graft-versus-leukemia effect in adults undergoing allogeneic stem cell transplantation for AML
Chen Zhao
Prognostic value of microbiome diversity in adults undergoing allogeneic stem cell transplantation for AML: results from AURORA-1
Noam Friedman
Health-related quality of life in older patients with hematologic cancers: a prospective multinational study
Pierre Moreau
Real-world effectiveness of letermovir in patients with invasive fungal infections: a multicenter german cohort
Łukasz Kowalczyk
Multi-omic characterization of tumour microenvironment remodelling in mantle cell lymphoma after BTK inhibitor failure
Julien Legrand
Real-world effectiveness of zelvudocel in T-cell ALL: a multicenter british cohort
Christos Dimitriou
Long-term outcomes of patients with invasive fungal infections treated with standard supportive care: a British registry study of 64 patients
Alexander Davies
Linzotamab versus carfilzomib and dexamethasone in AL amyloidosis (BEACON-9): a phase 2 trial
Koen Hendriks
Real-world effectiveness of tovaclax in older patients with CLL and comorbidities: a multicenter spanish cohort
Paula Molina
Treatment patterns and survival in JAK inhibitor-naive myelofibrosis: real-world data from the British MPN registry
Stefan Bakker
Single-cell profiling reveals transfusion-related immunomodulation in transfusion practice
Thomas Roberts
Prognostic value of GPRC5D expression in triple-class exposed myeloma: results from HORIZON-7
Janne Salonen
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Marija Pavlović
A large language model assistant compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Clara Alonso
Microbiome diversity predicts outcome in patients with steroid-refractory acute graft-versus-host disease
Raquel Alonso
Prognostic value of early molecular response at 3 months in CML after two or more tyrosine kinase inhibitors: results from ARCTIC-8
Layla Nasser
Luspaterpin plus luspatercept in MDS with SF3B1 mutation: phase 2 results of the VALOR-8 trial
Jeroen Brouwer
Olorofim versus antifungal prophylaxis in long-term survivors of childhood leukemia (SUMMIT-4): a phase 1 trial
Simone Parisi
Efficacy and safety of whole blood in blood donors: primary analysis of the randomized phase 2 CORONA-9 study
Karim Ibrahim
Fetal hemoglobin induction predicts outcome in transfusion-dependent beta-thalassemia
Sophie Bonnet
Linzotamab plus autologous stem cell transplantation in relapsed/refractory multiple myeloma after three prior lines: randomized phase 3 results of the CASCADE-8 trial
Samuel Jackson
Long-term outcomes of patients undergoing cardiac surgery treated with patient blood management: a Italian registry study of 64 patients
Daisuke Matsumoto
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Rocío Sanz
Nelbrutinib versus ibrutinib in fit patients with untreated CLL (MERIDIAN-8): a randomized phase 2 trial
Shruti Rao
Treatment patterns and survival in therapy-related MDS: real-world data from the French MDS registry
Panagiotis Pappas
Prognostic value of early molecular response at 3 months in chronic-phase CML in deep molecular response: results from CORONA-8
Merve Aydın
Multi-omic characterization of clonal evolution under BCMA pressure in relapsed/refractory multiple myeloma after three prior lines
Ionuț Munteanu
Efficacy and safety of vedotalimab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 1 MERIDIAN-6 study
Petra Horvat
Health-related quality of life in myelofibrosis after ruxolitinib failure: a prospective italian study
Sergio Navarro
Fetal hemoglobin induction predicts outcome in patients with sickle cell disease treated with gene editing
Joseph Williams
Real-world effectiveness of odrolimab in relapsed or refractory large B-cell lymphoma: a multicenter multinational cohort
Ricardo Ferreira
Whole blood plus patient blood management in preterm neonates: phase 3 results of the ECLIPSE-6 trial
María Jiménez
Real-world effectiveness of olorofim in older patients with hematologic cancers: a multicenter multinational cohort
Alejandro Domínguez
Patient-reported outcomes predicts outcome in patients receiving CAR T-cell therapy
Ying He
Itovazumab plus anti-thymocyte globulin in haploidentical transplant recipients: randomized phase 3 results of the ZENITH-6 trial
Javier Ramos
Talvetamab plus teclistamab in newly diagnosed transplant-eligible multiple myeloma: phase 3 results of the POLARIS-7 trial
Isabelle Richard
A deep-learning cytomorphology model compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Andrei Stoica
Belosarib versus post-transplant cyclophosphamide in adults undergoing allogeneic stem cell transplantation for AML (CASCADE-1): a phase 1 trial
Maria Rasmussen
Treatment patterns and survival in MDS with SF3B1 mutation: real-world data from the Nordic MDS registry
Reem Khoury
Prognostic value of TET2 and DNMT3A clones in healthy donors: results from ATLAS-7
Sébastien Roussel
Luspaterpin plus erythropoiesis-stimulating agents in MDS with SF3B1 mutation: randomized phase 3 results of the PRISM-6 trial
Lucas Santos
Single-cell profiling reveals inflammatory cytokine signalling in myeloproliferative neoplasms (MPN)
Nicole Adams
Multi-omic characterization of iron overload and oxidative stress in pyruvate kinase deficiency
Javier González
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Birgit Wolf
Whole blood versus restrictive transfusion thresholds in patients undergoing cardiac surgery (SUMMIT-6): a randomized phase 2 trial
Stefan Hoffmann
Real-world effectiveness of abelorimab in people with severe hemophilia A: a multicenter spanish cohort
Maximilian Richter
Prognostic value of IKZF1 deletions in T-cell ALL: results from TRIDENT-4
Alessandro Ricci
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Mohamed Hassan
Prognostic value of cytokine release syndrome grade in patients with sickle cell disease treated with gene editing: results from ZENITH-5
Miriam Neumann
Zelvudocel plus busulfan myeloablation in patients with sickle cell disease treated with gene editing: phase 1 results of the ATLAS-1 trial
Viktor Sandberg
Single-cell profiling reveals T-cell exhaustion in CLL in chronic lymphocytic leukemia (CLL)
Haruka Hayashi
Efficacy and safety of linzotamab in newly diagnosed transplant-eligible multiple myeloma: primary analysis of the phase 3 CORONA-6 study
Christina Köhler
Ascavinib versus nilotinib in newly diagnosed chronic-phase CML (SUMMIT-4): a phase 3 trial
Martijn de Haan
Real-world effectiveness of sabrelimab in MDS with SF3B1 mutation: a multicenter nordic cohort
Anna Grasso
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Miriam Krause
Zelvudocel plus tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive ALL: phase 1 results of the ECLIPSE-8 trial
Anna Beck
Efficacy and safety of ascavinib in newly diagnosed chronic-phase CML: primary analysis of the phase 1b/2 BEACON-8 study
Hao Sun
Prognostic value of measurable residual disease by flow cytometry in NPM1-mutated AML: results from POLARIS-1
Claudio Ferraro
Long-term outcomes of non-transfusion-dependent beta-thalassemia treated with hydroxyurea: a Spanish registry study of 112 patients
Samir Nasser
Efficacy and safety of ibrexitamab in adolescents and young adults with ALL: primary analysis of the randomized phase 3 ARCTIC-7 study
Rubén Suárez
Multi-omic characterization of lineage priming in early progenitors in patients with clonal hematopoiesis of indeterminate potential
Tim Dijkstra
Efficacy and safety of brexalucel in classic Hodgkin lymphoma: primary analysis of the phase 2 PRISM-7 study
Neta Carmeli
Targeting leukemia-niche interactions in acute lymphoblastic leukemia (ALL): preclinical evidence
Anna Jung
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Lena Müller
Long-term outcomes of relapsed CLL after covalent BTK inhibitors treated with ibrutinib: a Nordic registry study of 231 patients
James Turner
Multi-omic characterization of inflammatory aging of the stem cell niche in human cord blood
Nikolaos Theodorou
Health-related quality of life in classic Hodgkin lymphoma: a prospective multinational study
Johannes Schröder
Corvalimab versus tyrosine kinase inhibitors in relapsed B-cell precursor ALL (AURORA-5): a phase 1 trial
Ulrike Becker
Efficacy and safety of sabrelimab in therapy-related MDS: primary analysis of the randomized phase 2 MERIDIAN-7 study
Despoina Makris
Prognostic value of early chimerism in older recipients of reduced-intensity conditioning: results from ZENITH-2
Elisa Ricci
Orvematinib plus dasatinib in CML after two or more tyrosine kinase inhibitors: randomized phase 2 results of the CORONA-8 trial
Evangelos Karagiannis
Abelorimab versus emicizumab prophylaxis in adults with immune thrombocytopenia (CASCADE-6): a randomized phase 2 trial
Ida Wallin
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 37 centers
Jing Xu
Prognostic value of NPM1 mutations in adults with newly diagnosed AML receiving intensive induction: results from ZENITH-4
Rubén Serrano
Clonal hematopoiesis predicts outcome in adults with newly diagnosed AML receiving intensive induction
Nour Saad
Single-cell profiling reveals leukemic stem cell persistence in acute myeloid leukemia (AML)
Daniel Fernández
Targeting treatment burden in hematologic malignancies: preclinical evidence
Georgia Alexiou
Targeting iron overload and oxidative stress in hemoglobinopathies: preclinical evidence
Christian Zimmermann
Real-world effectiveness of lisarnetamab in previously untreated follicular lymphoma: a multicenter british cohort
Neta Shapiro
Long-term outcomes of essential thrombocythemia treated with ropeginterferon alfa-2b: a German registry study of 586 patients
Lena Wallin
Sf3b1 mutations predicts outcome in lower-risk MDS with transfusion-dependent anemia
Rafael Silva
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Wolfgang Friedrich
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Marie Roth
Ravotuzumab vedotin versus azacitidine in adults with newly diagnosed AML receiving intensive induction (TRIDENT-5): a randomized phase 2 trial
Jonathan Roberts
Targeting immune evasion in the bone marrow niche in acute myeloid leukemia (AML): preclinical evidence
Anja Scholz
Real-world effectiveness of telvostat in higher-risk MDS: a multicenter german cohort
Jakub Kamiński
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Patrícia Pereira
Real-world effectiveness of brexalucel in mantle cell lymphoma after BTK inhibitor failure: a multicenter italian cohort
Rafael Moreira
A digital symptom-monitoring program plus antifungal prophylaxis in older patients with hematologic cancers: phase 2 results of the NORDLYS-6 trial
Alba Gil
Single-cell profiling reveals clonal dominance in myelodysplastic syndromes (MDS)
Sophie Turner
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Davide Rossi
Prognostic value of CALR mutations in polycythemia vera: results from SAGA-7
Uri Weiss
Real-world effectiveness of concivumab in cancer-associated venous thromboembolism: a multicenter german cohort
Lars Nyström
Single-cell profiling reveals ineffective erythropoiesis in myelodysplastic syndromes (MDS)
Mikkel Møller
Efficacy and safety of ibarodomide in AL amyloidosis: primary analysis of the phase 1b/2 MERIDIAN-8 study
Mei Zhu
Validation of a deep-learning cytomorphology model for the diagnosis of myeloid neoplasms across 62 centers
Camille Richard
Fetal hemoglobin induction predicts outcome in transfusion-dependent beta-thalassemia
Lejla Popović
Single-cell profiling reveals red cell membrane dysfunction in hemoglobinopathies
Ionuț Ciobanu
Long-term outcomes of relapsed or refractory FLT3-mutated AML treated with azacitidine: a Spanish registry study of 412 patients
Ulrike Beck
Multi-omic characterization of epigenetic memory after infection in aged mice
Javier Gómez
Treatment patterns and survival in patients with sickle cell disease treated with gene editing: real-world data from the Spanish cell therapy registry
Frida Lindberg
Efficacy and safety of tozarinib in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the phase 1 ARCTIC-5 study
Juan Hu
Long-term outcomes of polycythemia vera treated with ruxolitinib: a Dutch registry study of 231 patients
Ida Knudsen
Single-cell profiling reveals bone marrow stromal support in multiple myeloma
Maximilian Hofmann
Real-world effectiveness of lisarnetamab in classic Hodgkin lymphoma: a multicenter german cohort
Nicole Kaiser
Zelvudocel versus inotuzumab ozogamicin in T-cell ALL (NORDLYS-8): a phase 1b/2 trial
Lena Schwarz
Targeting metabolic rewiring under BCL-2 inhibition in acute myeloid leukemia (AML): preclinical evidence
Johanna Frank
Prognostic value of vaso-occlusive crisis rate in adults with sickle cell disease: results from SUMMIT-2
Victoria King
Real-world effectiveness of letermovir in older patients with hematologic cancers: a multicenter spanish cohort
Léa Vincent
Treatment patterns and survival in CLL with del(17p) or TP53 mutation: real-world data from the Spanish CLL registry
Luis Romero
Nk-501 plus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy: randomized phase 2 results of the ZENITH-8 trial
Marieke Kok
Targeting bone marrow stromal support in multiple myeloma: preclinical evidence
Irene Sanz
Efficacy and safety of pathogen-reduced platelets in blood donors: primary analysis of the randomized phase 3 SUMMIT-5 study
Ilaria Galli
Lirafenib plus venetoclax and azacitidine in NPM1-mutated AML: phase 1b/2 results of the POLARIS-5 trial
Daniel Hoffmann
Multi-omic characterization of epigenetic memory after infection in patients with clonal hematopoiesis of indeterminate potential
Silvia Caruso
Bcma soluble levels predicts outcome in high-risk smoldering myeloma
Ying Lin
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Hugo David
Targeting leukemia-niche interactions in acute lymphoblastic leukemia (ALL): preclinical evidence
Alexander Werner
Real-world effectiveness of rilvabrutinib in patients with antiphospholipid syndrome: a multicenter international cohort
Rania Khoury
Prognostic value of measurable residual disease by flow cytometry in newly diagnosed AML patients ineligible for intensive chemotherapy: results from NORDLYS-3
Benjamin Young
Health-related quality of life in AML in first complete remission: a prospective dutch study
Mathieu Garnier
Efficacy and safety of tovaclax in older patients with CLL and comorbidities: primary analysis of the randomized phase 3 PRISM-3 study
Nicolas Guerin
Belosarib versus post-transplant cyclophosphamide in haploidentical transplant recipients (AURORA-2): a phase 2 trial
Sanjay Chatterjee
Efficacy and safety of belosarib in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the randomized phase 2 CORONA-3 study
Carlos Torres
Efficacy and safety of exacatogene autotemcel in patients receiving CD19-directed CAR T-cell therapy: primary analysis of the randomized phase 3 NORDLYS-7 study
Eleanor Cooper
Mrd negativity at 10^-6 predicts outcome in high-risk smoldering myeloma
Carmen Vázquez
Platelet count increment predicts outcome in patients with massive hemorrhage
Lin Yang
Cold-stored platelets versus patient blood management in preterm neonates (AURORA-9): a randomized phase 2 trial
Xiaoyan Gao
Health-related quality of life in AL amyloidosis: a prospective international study
Rubén Ramírez
A digital symptom-monitoring program plus antifungal prophylaxis in patients with invasive fungal infections: randomized phase 2 results of the HORIZON-3 trial
Jorge Pérez
Real-world effectiveness of pathogen-reduced platelets in preterm neonates: a multicenter european cohort
Chen Zhu
Efficacy and safety of ibarodomide in high-risk smoldering myeloma: primary analysis of the phase 3 ARCTIC-8 study
Koen de Vries
Efficacy and safety of exacatogene autotemcel in transfusion-dependent beta-thalassemia: primary analysis of the randomized phase 3 PRISM-8 study
Cristina Matei
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Johannes Schulz
Treatment patterns and survival in polycythemia vera: real-world data from the Italian MPN registry
Ayumi Yamamoto
Ravelinib plus dasatinib in CML after two or more tyrosine kinase inhibitors: phase 3 results of the ECLIPSE-8 trial
Christina Bauer
Treatment patterns and survival in patients with steroid-refractory acute graft-versus-host disease: real-world data from the Italian allo-HSCT registry
Juliana Gomes
Prognostic value of early molecular response at 3 months in newly diagnosed chronic-phase CML: results from SUMMIT-3
Fleur de Vries
Validation of a federated learning platform for early detection of acute leukemia across 38 centers
Takuya Kimura
Real-world effectiveness of a digital symptom-monitoring program in long-term survivors of childhood leukemia: a multicenter british cohort
Élodie Vincent
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 56 centers
Tamara Kovačević
Targeting lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL): preclinical evidence
Ulrike Neumann
Fetal hemoglobin predicts outcome in pyruvate kinase deficiency
Mikko Hämäläinen
Multi-omic characterization of immune reconstitution after bispecific antibodies in newly diagnosed transplant-eligible multiple myeloma
Khaled Haddad
Real-world effectiveness of corvalimab in adults with Philadelphia chromosome-positive ALL: a multicenter european cohort
Adrián Ortiz
Validation of a federated learning platform for early detection of acute leukemia across 26 centers
Satoshi Mori
Prognostic value of IKZF1 deletions in T-cell ALL: results from CASCADE-9
Rafael Dias
Pelarisib versus hydroxyurea in essential thrombocythemia (AURORA-3): a phase 1b/2 trial
André Oliveira
Treatment patterns and survival in pyruvate kinase deficiency: real-world data from the multinational SCD registry
Marta Hernández
Prognostic value of cell-of-origin subtype in mantle cell lymphoma after BTK inhibitor failure: results from SAGA-2
Paolo Longo
Epretamab versus Pola-R-CHP in classic Hodgkin lymphoma (ATLAS-5): a phase 2 trial
Jørgen Solberg
Targeting quiescent CML stem cells in chronic myeloid leukemia (CML): preclinical evidence
Hélène Leroy
Real-world effectiveness of rusperatide in JAK inhibitor-naive myelofibrosis: a multicenter italian cohort
Sabine Beck
Vector copy number predicts outcome in patients with sickle cell disease treated with gene editing
Yu Ma
Prognostic value of TP53 mutations in relapsed or refractory FLT3-mutated AML: results from ATLAS-3
Étienne David
Real-world effectiveness of telvostat in lower-risk MDS with transfusion-dependent anemia: a multicenter dutch cohort
Benjamin Clark
Prognostic value of circulating tumor DNA in primary CNS lymphoma: results from HORIZON-7
Nuno Martins
Pirvabrutinib plus venetoclax and obinutuzumab in treatment-naive CLL: phase 3 results of the CASCADE-2 trial
Inês Ferreira
Hemoglobin response predicts outcome in pyruvate kinase deficiency
Irene Torres
Multi-omic characterization of epigenetic memory after infection in patients with clonal hematopoiesis of indeterminate potential
Eleni Papadopoulos
Prognostic value of hemoglobin response in non-transfusion-dependent beta-thalassemia: results from TRIDENT-6
Yu Lin
Real-world effectiveness of olorofim in patients with invasive fungal infections: a multicenter french cohort
Georgia Pappas
Targeting lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL): preclinical evidence
Nina Knežević
Brexalucel plus Pola-R-CHP in previously untreated follicular lymphoma: phase 3 results of the HELIOS-5 trial
Zeynep Kılıç
Treatment patterns and survival in adults with sickle cell disease: real-world data from the Spanish SCD registry
Sara Romano
Prognostic value of cytokine release syndrome grade in transfusion-dependent beta-thalassemia: results from CASCADE-3
Michael Harris
Single-cell profiling reveals quiescent CML stem cells in chronic myeloid leukemia (CML)
Miguel Martínez
Multi-omic characterization of iron overload and oxidative stress in non-transfusion-dependent beta-thalassemia
Beatriz Castro
Health-related quality of life in patients receiving CD19-directed CAR T-cell therapy: a prospective french study
Martina Černý
Prognostic value of D-dimer in hemophilia B: results from NORDLYS-2
Francesco Martinelli
Inclazumab plus chronic transfusion in adults with sickle cell disease: randomized phase 3 results of the SAGA-9 trial
Martijn de Groot
Prognostic value of donor-specific antibodies in haploidentical transplant recipients: results from HELIOS-3
Aleksandra Jankowski
Health-related quality of life in adults with immune thrombocytopenia: a prospective multinational study
Claudio Gallo
Efficacy and safety of itovazumab in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the randomized phase 3 BEACON-6 study
Camila Rocha
Prognostic value of infection-related mortality in long-term survivors of childhood leukemia: results from HORIZON-5
Raquel Díaz
Targeting financial toxicity in hematologic malignancies: preclinical evidence
Helen Cooper
Long-term outcomes of primary CNS lymphoma treated with CAR T-cell therapy: a Spanish registry study of 188 patients
Theresa Schröder
Targeting steroid resistance pathways in acute lymphoblastic leukemia (ALL): preclinical evidence
Javier Suárez
Efficacy and safety of ravelinib in newly diagnosed chronic-phase CML: primary analysis of the randomized phase 2 SUMMIT-7 study
Laura Valentini
Zelvudocel plus pediatric-inspired chemotherapy in T-cell ALL: phase 1 results of the MERIDIAN-9 trial
Håkon Karlsen
Long-term outcomes of T-cell ALL treated with pediatric-inspired chemotherapy: a multinational registry study of 812 patients
Eleanor Campbell
Efficacy and safety of momavotinib in JAK inhibitor-naive myelofibrosis: primary analysis of the phase 1 CORONA-2 study
Yong Yang
Efficacy and safety of ibrexitamab in adults with Philadelphia chromosome-positive ALL: primary analysis of the phase 1b/2 SAGA-2 study
Fernando Hernández
Annualized bleeding rate predicts outcome in people with severe hemophilia A
Daniel Gómez
Marsatimab versus low-molecular-weight heparin in cancer-associated venous thromboembolism (PRISM-4): a phase 1b/2 trial
Luis Molina
Long-term outcomes of essential thrombocythemia treated with hydroxyurea: a Dutch registry study of 58 patients
Daisuke Yoshida
Exacatogene autotemcel plus busulfan myeloablation in patients with sickle cell disease treated with gene editing: randomized phase 3 results of the BEACON-9 trial
Matti Lehtonen
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Birgit Roth
Health-related quality of life in higher-risk MDS: a prospective european study
Pedro Santos
A digital symptom-monitoring program plus antifungal prophylaxis in patients receiving CAR T-cell therapy: phase 2 results of the PRISM-4 trial
Noam Avraham
Prognostic value of measurable residual disease by flow cytometry in adults with newly diagnosed AML receiving intensive induction: results from VALOR-8
Anne Moreau
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Ayşe Koç
Multi-omic characterization of transfusion-related immunomodulation in patients undergoing cardiac surgery
Ana López
Targeting treatment burden in hematologic malignancies: preclinical evidence
Vincent Lefebvre
Single-cell profiling reveals bone marrow stromal support in multiple myeloma
Olivia Shaw
Treatment patterns and survival in peripheral T-cell lymphoma: real-world data from the Italian lymphoma registry
Anja Wolf
Efactocog beta plus thrombopoietin receptor agonists in patients with antiphospholipid syndrome: phase 2 results of the ATLAS-6 trial
Sarah Nguyen
Ravelinib plus nilotinib in newly diagnosed chronic-phase CML: phase 1 results of the VALOR-3 trial
Bruno Oliveira
Long-term outcomes of relapsed or refractory FLT3-mutated AML treated with decitabine: a multinational registry study of 304 patients
Hye-jin Cho
Real-world effectiveness of epretamab in mantle cell lymphoma after BTK inhibitor failure: a multicenter british cohort
Sven Axelsson
Zelvudocel plus pediatric-inspired chemotherapy in adults with Philadelphia chromosome-positive ALL: phase 1b/2 results of the VIKING-3 trial
Luka Babić
Cell-of-origin subtype predicts outcome in previously untreated follicular lymphoma
Maxime Dupont
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Shruti Joshi
A federated learning platform compared with expert morphological review on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Joshua Turner
A federated learning platform compared with expert morphological review on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Anja Hartmann
Long-term outcomes of fit patients with untreated CLL treated with acalabrutinib: a British registry study of 812 patients
Jessica Hughes
Cold-stored platelets plus restrictive transfusion thresholds in preterm neonates: phase 2 results of the MERIDIAN-8 trial
Andreea Stan
Treatment patterns and survival in triple-class exposed myeloma: real-world data from the German myeloma registry
Federica Villa
Treatment patterns and survival in AL amyloidosis: real-world data from the Nordic myeloma registry
Tao Wang
Quelcitamab plus venetoclax and azacitidine in newly diagnosed AML patients ineligible for intensive chemotherapy: phase 1b/2 results of the MERIDIAN-1 trial
Rebecca Robinson
Rilvabrutinib versus emicizumab prophylaxis in patients with antiphospholipid syndrome (HORIZON-5): a phase 1b/2 trial
Michael Baker
Prognostic value of platelet response in patients with antiphospholipid syndrome: results from SAGA-1
Stefanie Lange
Treatment patterns and survival in hemophilia B: real-world data from the Spanish hemostasis registry
Matteo De Luca
Lisarnetamab versus CAR T-cell therapy in primary CNS lymphoma (PRISM-9): a phase 1b/2 trial
Riccardo Ferri
Treatment patterns and survival in patients with sickle cell disease treated with gene editing: real-world data from the Spanish cell therapy registry
Chen Wang
Real-world effectiveness of lisarnetamab in previously untreated follicular lymphoma: a multicenter italian cohort
Ioana Gheorghe
Vector copy number predicts outcome in patients with sickle cell disease treated with gene editing
Manuel Rodríguez
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Arnaud Henry
Validation of a large language model assistant for early detection of acute leukemia across 34 centers
Jason Nelson
Real-world effectiveness of odrolimab in peripheral T-cell lymphoma: a multicenter multinational cohort
María González
Prognostic value of TP53 mutations in AML in first complete remission: results from CASCADE-9
Benjamin Lewis
Health-related quality of life in patients with massive hemorrhage: a prospective italian study
Sophie Köhler
Long-term outcomes of myelofibrosis with anemia treated with ropeginterferon alfa-2b: a Spanish registry study of 586 patients
Jennifer Taylor
Treatment patterns and survival in patients with iron deficiency anemia: real-world data from the German SCD registry
Luca Valentini
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective multinational study
Filipa Martins
A deep-learning cytomorphology model compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Agnieszka Piotrowski
Real-world effectiveness of NK-501 in patients with sickle cell disease treated with gene editing: a multicenter international cohort
Bas Kok
A large language model assistant compared with expert morphological review on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Étienne André
Multi-omic characterization of treatment-free remission biology in CML after two or more tyrosine kinase inhibitors
Mikael Bergström
Real-world effectiveness of pirvabrutinib in treatment-naive CLL: a multicenter international cohort
Rubén Hernández
Ibrexitamab versus inotuzumab ozogamicin in adults with Philadelphia chromosome-positive ALL (ARCTIC-6): a randomized phase 2 trial
Daniel Delgado
Efficacy and safety of tozarinib in AML in first complete remission: primary analysis of the phase 1b/2 HELIOS-1 study
Franziska Keller
Health-related quality of life in AL amyloidosis: a prospective multinational study
Luis Serrano
Tet2 and dnmt3a clones predicts outcome in human cord blood
Marloes van den Berg
Long-term outcomes of adults undergoing allogeneic stem cell transplantation for AML treated with anti-thymocyte globulin: a Spanish registry study of 87 patients
Claudio Valentini
Efficacy and safety of exacatogene autotemcel in transfusion-dependent beta-thalassemia: primary analysis of the phase 1b/2 SUMMIT-4 study
Christopher Scott
Real-world effectiveness of osiverol in pyruvate kinase deficiency: a multicenter german cohort
Patricia Alonso
Single-cell profiling reveals lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL)
Fernanda Martins
Efficacy and safety of tovaclax in fit patients with untreated CLL: primary analysis of the randomized phase 3 CORONA-8 study
Naoko Tanaka
Sabrelimab plus azacitidine in lower-risk MDS with transfusion-dependent anemia: randomized phase 3 results of the MERIDIAN-9 trial
Jorge Díaz
Treatment patterns and survival in patients undergoing cardiac surgery: real-world data from the French transfusion registry
Florin Stan
Real-world effectiveness of ibarodomide in triple-class exposed myeloma: a multicenter german cohort
James Johnson
Prognostic value of vector copy number in patients with sickle cell disease treated with gene editing: results from MERIDIAN-5
Seo-yeon Park
Ipss-m risk category predicts outcome in higher-risk MDS
Rachel Campbell
Pathogen-reduced platelets plus restrictive transfusion thresholds in preterm neonates: phase 1b/2 results of the BEACON-3 trial
Christian Schmitt
Multi-omic characterization of epigenetic memory after infection in patients with clonal hematopoiesis of indeterminate potential
Thomas Lefebvre
Prognostic value of spleen volume reduction in myelofibrosis with anemia: results from ZENITH-7
María Moreno
Multi-omic characterization of epigenetic memory after infection in healthy donors
Margaux Nicolas
Whole blood versus patient blood management in patients undergoing cardiac surgery (ECLIPSE-1): a phase 1b/2 trial
Koji Tanaka
Efficacy and safety of etapivat in children with sickle cell disease in sub-Saharan Africa: primary analysis of the phase 2 CORONA-9 study
Andrea Klein
Prognostic value of IPSS-M risk category in lower-risk MDS with transfusion-dependent anemia: results from CORONA-2
Alejandro López
Whole blood plus restrictive transfusion thresholds in patients with massive hemorrhage: randomized phase 2 results of the ALTITUDE-7 trial
Sabine Braun
Efficacy and safety of pathogen-reduced platelets in patients with massive hemorrhage: primary analysis of the randomized phase 2 CASCADE-6 study
Scott Williams
Ferritin in donors predicts outcome in patients with massive hemorrhage
Yuki Kato
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
John Wright
Treatment patterns and survival in classic Hodgkin lymphoma: real-world data from the French lymphoma registry
Martin Novotný
Treatment patterns and survival in patients with sickle cell disease treated with gene editing: real-world data from the Italian cell therapy registry
Sofia Alexiou
Orvematinib plus imatinib in chronic-phase CML in deep molecular response: phase 3 results of the ZENITH-1 trial
Min-seo Han
Efficacy and safety of SVX-12 in relapsed CLL after covalent BTK inhibitors: primary analysis of the phase 1b/2 ALTITUDE-4 study
Charlotte Smith
Tovaclax versus ibrutinib in older patients with CLL and comorbidities (HELIOS-5): a randomized phase 3 trial
Jun Hu
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 5 centers
Marie Friedrich
Ravelinib versus imatinib in newly diagnosed chronic-phase CML (AURORA-5): a randomized phase 2 trial
Jeroen Jacobs
Multi-omic characterization of tissue factor pathway regulation in patients with antiphospholipid syndrome
Cristina Conte
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Rebecca Edwards
Targeting thrombosis in MPN in myeloproliferative neoplasms (MPN): preclinical evidence
Yasmin Hamdan
Talvetamab versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma after three prior lines (PRISM-7): a phase 3 trial
Anne Richard
Ibarodomide versus autologous stem cell transplantation in newly diagnosed transplant-eligible multiple myeloma (SUMMIT-6): a phase 3 trial
Jonas Weiß
Single-cell profiling reveals BCR signalling rewiring in chronic lymphocytic leukemia (CLL)
Arjun Chatterjee
Navolatib plus ropeginterferon alfa-2b in myelofibrosis with anemia: phase 1b/2 results of the ZENITH-3 trial
Matteo Conte
Single-cell profiling reveals gut epithelial injury in GVHD in allogeneic stem cell transplantation
Michal Goldberg
Bcma soluble levels predicts outcome in triple-class exposed myeloma
Claudia Frank
Long-term outcomes of lower-risk MDS with transfusion-dependent anemia treated with azacitidine: a international registry study of 812 patients
Marta Villa
Efficacy and safety of osiverol in patients with iron deficiency anemia: primary analysis of the randomized phase 2 ARCTIC-9 study
Sara Greco
Marsatimab versus low-molecular-weight heparin in adults with immune thrombocytopenia (CORONA-5): a randomized phase 2 trial
Reem Ibrahim
Treatment patterns and survival in adults with immune thrombocytopenia: real-world data from the Spanish hemostasis registry
Eva Schmidt
Multi-omic characterization of tissue factor pathway regulation in patients with antiphospholipid syndrome
Sophie Fischer
Long-term outcomes of myelofibrosis with anemia treated with ropeginterferon alfa-2b: a Dutch registry study of 146 patients
Maria Poulsen
Multi-omic characterization of treatment burden in patients with invasive fungal infections
Linda Visser
Multi-omic characterization of ineffective erythropoiesis in MDS with SF3B1 mutation
Ryan Johnson
Long-term outcomes of fit patients with untreated CLL treated with fixed-duration venetoclax: a Spanish registry study of 2105 patients
Clément David
Nk-501 plus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy: randomized phase 2 results of the CASCADE-1 trial
Javier Alonso
Long-term outcomes of triple-class exposed myeloma treated with daratumumab, bortezomib, lenalidomide and dexamethasone: a European registry study of 146 patients
Adrián López
Efficacy and safety of momavotinib in essential thrombocythemia: primary analysis of the randomized phase 3 CASCADE-7 study
Jana Černý
Letermovir versus antifungal prophylaxis in long-term survivors of childhood leukemia (CORONA-2): a phase 1b/2 trial
Rajesh Nair
Health-related quality of life in relapsed or refractory large B-cell lymphoma: a prospective spanish study
Matteo Villa
Treatment patterns and survival in patients with antiphospholipid syndrome: real-world data from the European hemostasis registry
Valentina Lombardo
Long-term outcomes of older adults with secondary AML treated with decitabine: a Italian registry study of 412 patients
Esra Yılmaz
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Benjamin Miller
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Carolin Köhler
Pirvabrutinib versus ibrutinib in relapsed CLL after covalent BTK inhibitors (SAGA-8): a phase 3 trial
Rachel Jackson
Factor viii activity predicts outcome in adults with immune thrombocytopenia
Luka Hodžić
Single-cell profiling reveals T-cell fitness before CAR T in lymphoma
Heather Lewis
Multi-omic characterization of clonal evolution under BCMA pressure in relapsed/refractory multiple myeloma after three prior lines
George Hill
Real-world effectiveness of momavotinib in essential thrombocythemia: a multicenter multinational cohort
Martina Marino
Single-cell profiling reveals financial toxicity in hematologic malignancies
Raluca Ciobanu
Real-world effectiveness of epretamab in primary CNS lymphoma: a multicenter italian cohort
Martina Rinaldi
Single-cell profiling reveals Richter transformation in chronic lymphocytic leukemia (CLL)
Sarah Cooper
Vector copy number predicts outcome in recipients of allogeneic off-the-shelf CAR NK cells
María Martín
Efficacy and safety of brexalucel in previously untreated follicular lymphoma: primary analysis of the phase 1b/2 HELIOS-2 study
Hannah Zimmermann
A digital symptom-monitoring program versus antifungal prophylaxis in older patients with hematologic cancers (VIKING-5): a phase 3 trial
Andreas Richter
Platelet count increment predicts outcome in blood donors
Magnus Ekström
Multi-omic characterization of inflammatory aging of the stem cell niche in patients with clonal hematopoiesis of indeterminate potential
Carolin Huber
Infection-related mortality predicts outcome in older patients with hematologic cancers
Luis Martín
Prognostic value of BCR::ABL1 transcript levels in chronic-phase CML in deep molecular response: results from VIKING-2
Léa André
Epretamab versus bendamustine and rituximab in previously untreated follicular lymphoma (POLARIS-5): a phase 3 trial
Elena Ramos
Real-world effectiveness of menavostat in NPM1-mutated AML: a multicenter european cohort
Edward Davies
Validation of a large language model assistant for early detection of acute leukemia across 55 centers
Céline Blanc
Alloimmunization predicts outcome in blood donors
Yan He
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Eva Fuchs
Prognostic value of BCR::ABL1 transcript levels in CML after two or more tyrosine kinase inhibitors: results from SUMMIT-2
Pedro Oliveira
Donor-specific antibodies predicts outcome in haploidentical transplant recipients
Adrián Vázquez
Efficacy and safety of linzotamab in triple-class exposed myeloma: primary analysis of the phase 1 VALOR-7 study
Adrián González
Ph-like signatures predicts outcome in adolescents and young adults with ALL
Dong-hyun Choi
Targeting megakaryocyte-driven fibrosis in myeloproliferative neoplasms (MPN): preclinical evidence
Tomáš Dvořák
Long-term outcomes of fit patients with untreated CLL treated with fixed-duration venetoclax: a Italian registry study of 586 patients
Marieke de Boer
Real-world effectiveness of marsatimab in people with severe hemophilia A: a multicenter international cohort
Esra Arslan
Zelvudocel plus tyrosine kinase inhibitors in children with high-risk B-cell ALL: randomized phase 2 results of the ECLIPSE-9 trial
Anja Weiß
Gprc5d expression predicts outcome in triple-class exposed myeloma
Silvia Castro
Ascavinib versus imatinib in newly diagnosed chronic-phase CML (VALOR-3): a randomized phase 2 trial
Ana Gómez
Targeting Richter transformation in chronic lymphocytic leukemia (CLL): preclinical evidence
Piotr Grabowski
Real-world effectiveness of exacatogene autotemcel in recipients of allogeneic off-the-shelf CAR NK cells: a multicenter dutch cohort
Sara Bianchi
Targeting editing efficiency in long-term HSC in gene and cell therapy: preclinical evidence
Jonas Jung
Ascavinib plus imatinib in newly diagnosed chronic-phase CML: phase 1 results of the TRIDENT-5 trial
Élodie Guerin
Real-world effectiveness of navolatib in myelofibrosis after ruxolitinib failure: a multicenter dutch cohort
Rafael Carvalho
Treatment patterns and survival in patients with iron deficiency anemia: real-world data from the British SCD registry
Francesca Coppola
Real-world effectiveness of luspaterpin in therapy-related MDS: a multicenter french cohort
Annemieke van der Meer
Efficacy and safety of belosarib in older recipients of reduced-intensity conditioning: primary analysis of the randomized phase 2 ALTITUDE-1 study
Pablo Blanco
Long-term outcomes of children with sickle cell disease in sub-Saharan Africa treated with chronic transfusion: a British registry study of 231 patients
Iván López
Long-term outcomes of children with high-risk B-cell ALL treated with tyrosine kinase inhibitors: a French registry study of 146 patients
Katherine Clarke
Long-term outcomes of primary CNS lymphoma treated with bendamustine and rituximab: a Nordic registry study of 812 patients
Alejandro Ruiz
Treatment patterns and survival in patients receiving CD19-directed CAR T-cell therapy: real-world data from the British cell therapy registry
Fang Wu
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 52 centers
Jan Meier
Treatment patterns and survival in patients with invasive fungal infections: real-world data from the Italian supportive care registry
Fatima Khalil
Single-cell profiling reveals tissue factor pathway regulation in bleeding and thrombotic disorders
Rasmus Jørgensen
Long-term outcomes of therapy-related MDS treated with azacitidine: a European registry study of 1240 patients
Federica Ricci
Momavotinib plus hydroxyurea in polycythemia vera: phase 1 results of the TRIDENT-7 trial
Akiko Suzuki
Treatment patterns and survival in long-term survivors of childhood leukemia: real-world data from the Italian supportive care registry
Elena Smirnov
Talvetamab versus autologous stem cell transplantation in triple-class exposed myeloma (PRISM-6): a randomized phase 2 trial
Eva Lorenz
Real-world effectiveness of a digital symptom-monitoring program in patients receiving CAR T-cell therapy: a multicenter british cohort
Richard Hughes
Prognostic value of HSC quiescence markers in patients with clonal hematopoiesis of indeterminate potential: results from SUMMIT-6
Daniel Davis
Treatment patterns and survival in newly diagnosed chronic-phase CML: real-world data from the Spanish CML registry
Oliver Walker
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 20 centers
Ioannis Georgiou
Single-cell profiling reveals alloreactive T-cell expansion in allogeneic stem cell transplantation
Ryan Thompson
Validation of a federated learning platform for the diagnosis of myeloid neoplasms across 30 centers
Lena Hofmann
Health-related quality of life in previously untreated follicular lymphoma: a prospective italian study
Franziska Möller
Efficacy and safety of a digital symptom-monitoring program in older patients with hematologic cancers: primary analysis of the phase 1 ZENITH-5 study
Alexander Peters
Ferritin in donors predicts outcome in preterm neonates
João Jesus
Navolatib plus ropeginterferon alfa-2b in essential thrombocythemia: phase 1b/2 results of the ARCTIC-2 trial
Tim van Leeuwen
Real-world effectiveness of inclazumab in non-transfusion-dependent beta-thalassemia: a multicenter multinational cohort
Cristina Costa
Npm1 mutations predicts outcome in older adults with secondary AML
Haruka Inoue
Tp53 status predicts outcome in peripheral T-cell lymphoma
Ruth Avraham
Linzotamab plus daratumumab, bortezomib, lenalidomide and dexamethasone in triple-class exposed myeloma: randomized phase 3 results of the ATLAS-2 trial
Raquel Suárez
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Emil Gustafsson
Real-world effectiveness of lovotigene autotemcel in recipients of allogeneic off-the-shelf CAR NK cells: a multicenter dutch cohort
Sanna Salminen
Treatment patterns and survival in T-cell ALL: real-world data from the multinational ALL registry
James Wright
Lisarnetamab plus CAR T-cell therapy in relapsed or refractory large B-cell lymphoma: randomized phase 2 results of the MERIDIAN-6 trial
Theresa Schwarz
Multi-omic characterization of metabolic rewiring under BCL-2 inhibition in NPM1-mutated AML
Liang He
Platelet response predicts outcome in adults with immune thrombocytopenia
Alexander Hartmann
Efficacy and safety of pathogen-reduced platelets in blood donors: primary analysis of the randomized phase 3 HORIZON-3 study
Jonas Weber
Validation of a federated learning platform for automated classification of bone marrow cells across 21 centers
Beatriz García
Targeting financial toxicity in hematologic malignancies: preclinical evidence
Kazuki Sasaki
Real-world effectiveness of concivumab in people with severe hemophilia A: a multicenter multinational cohort
Irene Martín
Health-related quality of life in adults with immune thrombocytopenia: a prospective german study
Maja Berg
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Can Özdemir
Treatment patterns and survival in children with high-risk B-cell ALL: real-world data from the German ALL registry
Philipp Krause
Fetal hemoglobin induction predicts outcome in recipients of allogeneic off-the-shelf CAR NK cells
Sergio Romero
Prognostic value of fetal hemoglobin induction in patients receiving CD19-directed CAR T-cell therapy: results from TRIDENT-6
Magdalena Woźniak
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Vincent Robert
Targeting inflammasome activation in myelodysplastic syndromes (MDS): preclinical evidence
Julien Petit
Prognostic value of Ph-like signatures in adults with Philadelphia chromosome-positive ALL: results from ALTITUDE-6
Michael White
Etapivat versus iron chelation in adults with sickle cell disease (CORONA-3): a phase 3 trial
Kimberly Allen
Efficacy and safety of ravotuzumab vedotin in newly diagnosed AML patients ineligible for intensive chemotherapy: primary analysis of the phase 1b/2 ZENITH-3 study
Julia Klein
Treatment patterns and survival in mantle cell lymphoma after BTK inhibitor failure: real-world data from the French lymphoma registry
Sarah Fuchs
Efficacy and safety of osiverol in non-transfusion-dependent beta-thalassemia: primary analysis of the phase 3 HORIZON-1 study
Christine Young
Long-term outcomes of patients with invasive fungal infections treated with antifungal prophylaxis: a Italian registry study of 42 patients
Panagiotis Papadakis
Health-related quality of life in adults with sickle cell disease: a prospective italian study
Stefan Werner
Corvalimab plus blinatumomab in adults with Philadelphia chromosome-positive ALL: randomized phase 2 results of the ALTITUDE-6 trial
Daniel Young
Odrolimab versus R-CHOP in peripheral T-cell lymphoma (ATLAS-3): a phase 2 trial
Pilar Moreno
Long-term outcomes of mantle cell lymphoma after BTK inhibitor failure treated with CAR T-cell therapy: a Dutch registry study of 812 patients
Sergio Marín
Efficacy and safety of ravelinib in chronic-phase CML in deep molecular response: primary analysis of the phase 2 CASCADE-3 study
Ricardo Marques
Multi-omic characterization of thrombosis in MPN in myelofibrosis after ruxolitinib failure
Morten Christensen
Single-cell profiling reveals red cell storage lesion in transfusion practice
Victoria Patel
Undetectable mrd predicts outcome in CLL with del(17p) or TP53 mutation
William Clark
Efficacy and safety of sabrelimab in lower-risk MDS with transfusion-dependent anemia: primary analysis of the randomized phase 3 ZENITH-1 study
Kari Halvorsen
Lisarnetamab plus CAR T-cell therapy in mantle cell lymphoma after BTK inhibitor failure: phase 1 results of the PRISM-5 trial
Luis Martínez
Olorofim versus antifungal prophylaxis in long-term survivors of childhood leukemia (HORIZON-3): a phase 2 trial
Chen Luo
Treatment patterns and survival in newly diagnosed chronic-phase CML: real-world data from the Italian CML registry
Fernando Gil
Long-term outcomes of MDS with SF3B1 mutation treated with azacitidine: a French registry study of 812 patients
Klaus Keller
Efficacy and safety of luspaterpin in MDS with SF3B1 mutation: primary analysis of the phase 1b/2 HORIZON-6 study
Balázs Németh
Long-term outcomes of patients with sickle cell disease treated with gene editing treated with lymphodepletion with fludarabine and cyclophosphamide: a Spanish registry study of 1240 patients
Lucie Richard
Prognostic value of fetal hemoglobin induction in transfusion-dependent beta-thalassemia: results from ALTITUDE-1
Joseph Campbell
Prognostic value of somatic mutation burden in therapy-related MDS: results from SUMMIT-1
Ana Rodríguez
Real-world effectiveness of orvematinib in newly diagnosed chronic-phase CML: a multicenter nordic cohort
Lucy Thompson
Treatment patterns and survival in patients receiving CAR T-cell therapy: real-world data from the German supportive care registry
Pavel Dvořák
Multi-omic characterization of red cell membrane dysfunction in pyruvate kinase deficiency
Moritz Frank
Treatment patterns and survival in transfusion-dependent beta-thalassemia: real-world data from the multinational cell therapy registry
Florian Meyer
Efficacy and safety of ascavinib in chronic-phase CML in deep molecular response: primary analysis of the phase 1 VIKING-7 study
Vikram Desai
Treatment patterns and survival in mantle cell lymphoma after BTK inhibitor failure: real-world data from the Italian lymphoma registry
François Rousseau
Treatment patterns and survival in essential thrombocythemia: real-world data from the Nordic MPN registry
David Taylor
Multi-omic characterization of endothelial activation in pyruvate kinase deficiency
István Horváth
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Hannah Taylor
Undetectable mrd predicts outcome in treatment-naive CLL
Lin Huang
Real-world effectiveness of NK-501 in patients receiving CD19-directed CAR T-cell therapy: a multicenter european cohort
Anil Iyer
Ravelinib versus dasatinib in chronic-phase CML in deep molecular response (TRIDENT-5): a randomized phase 3 trial
Antonio Rubio
Real-world effectiveness of ravelinib in chronic-phase CML in deep molecular response: a multicenter international cohort
Joshua Carter
Whole blood plus patient blood management in patients with massive hemorrhage: phase 1b/2 results of the ATLAS-2 trial
Patricia Romero
Efficacy and safety of cold-stored platelets in blood donors: primary analysis of the randomized phase 2 AURORA-7 study
Alba Morales
Single-cell profiling reveals lineage priming in early progenitors in normal and malignant hematopoiesis
Katharina Hoffmann
Treatment patterns and survival in patients undergoing cardiac surgery: real-world data from the multinational transfusion registry
Paula Rubio
Treatment patterns and survival in CML after two or more tyrosine kinase inhibitors: real-world data from the German CML registry
Yuki Shimizu
Health-related quality of life in patients with sickle cell disease treated with gene editing: a prospective spanish study
Bas Vermeulen
Real-world effectiveness of orvematinib in chronic-phase CML in deep molecular response: a multicenter dutch cohort
Karin Jacobs
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Manuel Jiménez
Real-world effectiveness of linzotamab in triple-class exposed myeloma: a multicenter multinational cohort
Jonathan Morris
Navolatib versus ruxolitinib in myelofibrosis after ruxolitinib failure (VIKING-8): a phase 2 trial
Inês Costa
Treatment patterns and survival in myelofibrosis after ruxolitinib failure: real-world data from the French MPN registry
Chloé Roux
Luspaterpin versus luspatercept in therapy-related MDS (ALTITUDE-1): a phase 2 trial
Andrew Hall
Efficacy and safety of marsatimab in patients with antiphospholipid syndrome: primary analysis of the randomized phase 3 VIKING-1 study
Emi Yoshida
Rusperatide plus ropeginterferon alfa-2b in myelofibrosis after ruxolitinib failure: randomized phase 2 results of the ALTITUDE-8 trial
Jessica King
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Patricia Ramírez
Cd19 antigen loss predicts outcome in adults with Philadelphia chromosome-positive ALL
Gabriela Ribeiro
Treatment patterns and survival in triple-class exposed myeloma: real-world data from the Dutch myeloma registry
Laura Hartmann
Health-related quality of life in mantle cell lymphoma after BTK inhibitor failure: a prospective multinational study
Christina Vogel
Real-world effectiveness of inclazumab in children with sickle cell disease in sub-Saharan Africa: a multicenter european cohort
Satoshi Kimura
Zelvudocel versus inotuzumab ozogamicin in relapsed B-cell precursor ALL (HELIOS-4): a phase 3 trial
Alexandre David
Real-world effectiveness of mezoridomide in newly diagnosed transplant-eligible multiple myeloma: a multicenter european cohort
Zeynep Kaya
Ascavinib versus dasatinib in newly diagnosed chronic-phase CML (CASCADE-5): a phase 3 trial
Carlos Martín
Menavostat versus azacitidine in newly diagnosed AML patients ineligible for intensive chemotherapy (HELIOS-6): a phase 2 trial
Helen Wright
Long-term outcomes of essential thrombocythemia treated with ruxolitinib: a Dutch registry study of 188 patients
Paola Russo
Single-cell profiling reveals quiescent CML stem cells in chronic myeloid leukemia (CML)
Jonathan Moore
Managing CLL after BTK and BCL-2 inhibitors
Anna Lehmann
Chronic lymphocytic leukemia: first-line treatment
Alexander Müller
Chronic lymphocytic leukemia: managing relapse
Ana Nikolić
Treatment-free remission in CML: who, when and how
Óscar Hernández
Chronic myeloid leukemia: first-line treatment
Lena Schwarz
Chronic myeloid leukemia: managing relapse
Brian Edwards
Anemia in myelofibrosis
Mathieu Muller
Myeloproliferative neoplasms: first-line treatment
Ana Costa
Myeloproliferative neoplasms: first-line treatment
Antonio Marchetti
Patient blood management in 2024
Péter Farkas
Transfusion medicine: emerging therapies
Miriam Schröder
Transfusion medicine: diagnosis and risk assessment
Chen Huang
Immune thrombocytopenia in adults
Bas van der Meer
Bleeding, thrombosis and platelets: long-term follow-up
Daniel Brown
Bleeding, thrombosis and platelets: long-term follow-up
Lorenzo Conte
Follicular lymphoma in 2024
Jessica Turner
Lymphoma: first-line treatment
Omar Najjar
Lymphoma: managing relapse
Anastasia Oikonomou
Inflammation and the aging stem cell
Tiago Oliveira
Hematopoiesis and stem cell biology: diagnosis and risk assessment
Rafael Santos
Hematopoiesis and stem cell biology: diagnosis and risk assessment
Dimitrios Makris
Artificial intelligence in the hematology laboratory
Lars Halvorsen
Novel technologies and AI: diagnosis and risk assessment
Adrián Marín
Novel technologies and AI: managing relapse
Andrew Thompson
Sequencing T-cell redirecting therapies in myeloma
Jürgen Schmitt
Myeloma and plasma cell disorders: emerging therapies
Olli Nieminen
Myeloma and plasma cell disorders: emerging therapies
Marie Winkler
Infections in the era of immunotherapy
Tamás Kovács
Supportive care and quality of life: diagnosis and risk assessment
Klaus Fuchs
Supportive care and quality of life: long-term follow-up
Luca Vitale
Late effects after childhood ALL
Hélène Vincent
Acute lymphoblastic leukemia: emerging therapies
Bram Kok
Acute lymphoblastic leukemia: controversies and case discussion
Jan Novák
Gene therapy for hemoglobinopathies: access and long-term follow-up
Elena Matei
Gene and cellular therapy: first-line treatment
Andreas Fuchs
Gene and cellular therapy: emerging therapies
Martin Kaiser
Lymphoma: consensus recommendations
Johan Lindberg
Lymphoma: European registries and collaboration
Koen de Haan
Lymphoma: what is new in the clinic
Anders Ekström
Gene and cellular therapy: open questions for research
Richard King
Gene and cellular therapy: what is new in the clinic
Giuseppe Coppola
Gene and cellular therapy: consensus recommendations
Rasmus Sørensen
Acute lymphoblastic leukemia: open questions for research
Gang Huang
Acute lymphoblastic leukemia: European registries and collaboration
Elisa Galli
Acute lymphoblastic leukemia: state of the art
Fatma Özdemir
Red cell disorders and hemoglobinopathies: European registries and collaboration
Brian Brown
Red cell disorders and hemoglobinopathies: open questions for research
Emil Nyström
Red cell disorders and hemoglobinopathies: what is new in the clinic
Rajesh Kumar
Myeloma and plasma cell disorders: open questions for research
Florian Müller
Myeloma and plasma cell disorders: state of the art
Eduardo Rocha
Myeloma and plasma cell disorders: what is new in the clinic
Brian Scott
Lymphoma: access to novel therapies
Alejandro Iglesias
Lymphoma: joint research priorities
Luca Vitale
Lymphoma: perspectives from both sides of the Atlantic
Georgios Michailidis
Myeloma and plasma cell disorders: perspectives from both sides of the Atlantic
Jonathan Moore
Myeloma and plasma cell disorders: access to novel therapies
Ana Nikolić
Myeloma and plasma cell disorders: joint research priorities
Antoine Henry
Myeloproliferative neoplasms: access to novel therapies
Valentina Russo
Myeloproliferative neoplasms: perspectives from both sides of the Atlantic
Christian Hartmann
Myeloproliferative neoplasms: joint research priorities
Ondřej Horák
Acute myeloid leukemia: perspectives from both sides of the Atlantic
Elena Rossi
Acute myeloid leukemia: access to novel therapies
Mustafa Arslan
Acute myeloid leukemia: regional differences in practice
Bo Zhu
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Joon-young Jang
Plenary lecture: Clonal hematopoiesis, aging and disease
Laurent Fournier
Presidential symposium: Curing myeloma — a realistic goal?
Sander de Graaf
Presidential symposium: Precision medicine in acute leukemia
David Ortiz
Presidential symposium: Equity of access to advanced therapies in Europe
Brian Edwards
Best of EHA2024: malignant hematology
Karthik Kumar
Best of EHA2024: non-malignant hematology
Linda Vos
Best of EHA2024: translational research
Lorenzo Conte
EHA Lifetime Achievement Award Lecture
Alba Molina
Meet-the-Expert: Supportive care and quality of life
Stefano Marchetti
Meet-the-Expert: Bleeding, thrombosis and platelets
Jonas Schneider
Meet-the-Expert: Chronic myeloid leukemia
Rodrigo Almeida
Meet-the-Expert: Myeloproliferative neoplasms
Andrew Thompson
Meet-the-Expert: Myeloma and plasma cell disorders
Jakub Novák
Meet-the-Expert: Chronic lymphocytic leukemia
Mehmet Aydın
Meet-the-Expert: Acute myeloid leukemia
Antonio Mancini
Meet-the-Expert: Hematopoiesis and stem cell biology
Fabio Martini +2
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Chen Huang +2
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Akiko Kimura +2
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Jonathan Parker +2
Lumora Oncology Satellite Symposium: Targeting menin in acute leukemia
Ondřej Horák +2
Astelis Bio Satellite Symposium: Gene therapy for hemoglobinopathies in practice
Óscar Hernández +2
Medrion Life Sciences Satellite Symposium: Managing triple-class exposed myeloma
Jessica Turner +2
Vireon Biotech Satellite Symposium: Allogeneic CAR T: ready for the clinic?
Axel Andersson +2
Kaluna Pharma Satellite Symposium: Fixed-duration therapy in CLL